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ABSTRACT
The purpose of this study was to clinically evaluate the sedative effects of different doses of acepromazine-
xylazine combinations with or without atropine in dogs. One hundred and twenty dogs of various breeds and 
both sexes were used in a prospective randomized, blinded clinical study. Dogs, presented to the Veterinary 
Clinic for various diagnostic and surgical procedures, were randomly divided into four groups (n=30/group) 
and received the following drug combinations intramuscularly: Group AX: acepromazine (0.05 mg kg-1) + 
Xylazine (0.5 mg kg-1), Group AXA: Acepromazine (0.05 mg kg-1) + Xylazine (0.5 mg kg-1) + Atropine (0.04 
mg kg-1) Group LA-HX: Acepromazine (Low dose: 0.03 mg kg-1) + Xylazine (High dose: 0.8 mg kg-1), Group 
HA-LX: Acepromazine (High dose: 0.08 mg kg-1) + Xylazine (Low dose: 0.3 mg kg-1). Heart and respiratory 
rates, electrocardiogram and rectal temperature were recorded before drug injection (baseline) and during 
maximum sedation. Sedation was scored using descriptive categories. Heart rate signifi cantly decreased from 
the baseline following sedation in the AX, LA-HX and HA-LX groups. A signifi cant reduction in respiratory 
rate was observed in all treatment groups. The median sedation score did not differ signifi cantly between the 
groups; however, the quality of sedation was enhanced when atropine was added to the acepromazine-xylazine 
combination and a higher number of dogs were assigned score 3 in AXA group. No adverse effects were 
recorded during the study. The acepromazine-xylazine combination, particularly with atropine, can be used 
effectively for sedation and premedication before general anaesthesia in healthy dogs.
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Introduction
Tranquilizers and sedatives are commonly used in veterinary practice to facilitate 
handling and as premedication before general anaesthesia in small animals. Phenothiazine 
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agents and α2 agonists are often used to reduce anxiety and produce sedation in dogs 
(LEMKE, 2007).
Acepromazine, a phenothiazine derivative, is a potent neuroleptic agent with relatively 
low toxicity. It induces mild to moderate tranquilization, muscle relaxation and a decrease 
in spontaneous activity attributable principally to central dopaminergic antagonism. 
Acepromazine possesses antiemetic, anticonvulsant, antispasmodic, hypotensive and 
hypothermic properties (LEMKE, 2007). Although acepromazine is generally avoided in 
dogs with histories of seizures, no evidence is available to confi rm that it lowers the 
convulsive seizure threshold in dogs (TOBIAS et al., 2006). Acepromazine effectively 
prevents cardiac dysrhythmia and ventricular fi brillation in dogs during barbiturate and 
halothane anaesthesia (MUIR et al., 1975; DYSON and PETTIFER, 1997).
Xylazine was the fi rst α2-adrenergic agonist to be used as a sedative and analgesic 
in veterinary practice. Its sedative and analgesic activities are related to CNS depression 
mediated by stimulation of α2-adrenergic receptors (HSU et al., 1985). Sedative doses of 
xylazine cause heart rate and cardiac output to decrease signifi cantly in dogs, while blood 
pressure and peripheral vascular resistance initially increase, followed by a longer lasting 
hypotension (KLIDE et al., 1975; MUIR and PIPER., 1977; ILBACK and STALHANDSKE, 
2003). Emesis may occur in dogs and cats after xylazine administration by either the IM 
or SC route, which may be caused by activation of central α2 receptors (LEMKE, 2007).
Atropine, an anticholinergic agent, blocks muscarinic receptors at the postganglionic 
terminations of cholinergic fi bers in the autonomic nervous system. Atropine increases 
the incidence of cardiac dysrhythmia and sinus tachycardia in dogs (MUIR, 1978). 
Anticholinergics have been used to prevent bradycardia caused by administration of α2-
agonists in dogs (SHORT, 1991; KO et al., 2001).
Excited or aggressive dogs are not good candidates for acepromazine administration, 
because phenothiazines produce only mild sedation and are not effective in these 
circumstances. A higher dose of acepromazine does not increase sedation, but prolongs 
the side effects. Acepromazine is not reversible and does not provide analgesia. For these 
reasons, it is best to administer acepromazine in conjunction with opioid analgesics as part 
of a balanced regimen (STEPIEN et al., 1995; BARNHART et al., 2000). However, opioids 
are controlled substances and may not be readily available in some private practices. 
A combination of acepromazine and xylazine has been used in horses (MUIR et al., 
1979; NILSFORS et al., 1988; HUBBELL et al., 1999) and dogs (CRONIN et al., 1983). This 
combination is reported to produce rapid and better quality sedation in horses compared 
to when either drug is used alone (MUIR et al., 1979). The combination of acepromazine 
and xylazine, that exert different mechanisms of action, can increase sedative effects, 
yet decrease the side effects of these drugs. For example, acepromazine has antiemetic 
and antiarrhythmic effects, while xylazine can cause vomiting and cardiac arrhythmias 
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(LEMKE, 2007). Unlike acepromazine, xylazine has both profound sedative and some 
analgesic properties and can be used in excited and restless dogs. Its effects are reversible 
with the selective α2 adrenergic antagonists (GROSS, 2001; LEMKE, 2007). The peak effects 
of xylazine occur within 15 min, while 30 to 60 min should be allowed for maximal 
sedative effects to occur after SC or IM injection of acepromazine. This drug combination 
may result in more predictable and effective sedation and analgesia and fewer side effects 
due to the lower doses required.
To our knowledge, no clinical evaluation of the sedative and cardiorespiratory effects 
of the acepromazine and xylazine drug combination in dogs has been published. The 
purpose of the study reported here was to evaluate the sedative and cardiopulmonary 
effects of clinical doses of acepromazine-xylazine combinations with or without atropine 
in conscious dog.
Materials and methods 
One hundred and twenty, 2.0 ± 1.8 [range: 0.25-11] year old client-owned dogs of 
various breeds and both sexes (74 males, 46 females), weighing 18.1 ± 8.6 [range: 3.2-
47] kg that were presented to the Veterinary Clinic for a variety of diagnostic and surgical 
procedures, were included in this study. Based on physical examination and medical 
history, dogs were all classed as ASA (American Society of Anesthesiologists) I-II. This 
study was approved by the Research Animal Care and Use Committee of the School of 
Veterinary Medicine, Shiraz University. The animals were randomly divided into four 
groups (n = 30) and received the following drug combinations intramuscularly. Each 
dog was randomly assigned to one of four groups to receive equal volumes of different 
combinations: 
Group 1 (AX): Acepromazine maleate (Castran, Interchemie, Holland) (0.05 mg kg-1) 
+ Xylazine hydrochloride (Alfasan, Woerden, Holland) (0.5 mg kg-1)
Group 2 (AXA): Acepromazine (0.05 mg kg-1) + Xylazine (0.5 mg kg-1) + Atropine 
(Alfasan, Woerden, Holland) (0.04 mg kg-1) 
Group 3 (LA-HX): Acepromazine (Low dose: 0.03 mg kg-1) + Xylazine (High dose: 
0.8 mg kg-1) 
Group 4 (HA-LX): Acepromazine (High dose: 0.08 mg kg-1) + Xylazine (Low dose: 
0.3 mg kg-1).
All drugs were mixed in the same syringe before use and injected intramuscularly into 
the thigh muscles. The fi nal volume of drug combination was corrected to a standardized 
volume so that each dog received the same volume of 0.1 mL kg-1 (or 1 mL 10 kg-1). 
Following drug administration, the animals were left undisturbed for 15-20 minutes in a 
calm environment.
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Heart rate (HR), respiratory rate (RR), rectal temperature and electrocardiogram 
(ECG) were recorded before drug administration and during maximal sedative effects; 
i.e., 15-20 min after drug administration. During ECG recording, dogs were placed in 
right lateral recumbency. The three standard bipolar limb leads, I, II and III were recorded 
on paper with an electrocardiograph (Cardiostat 701, Simens, Germany). The paper speed 
and sensitivity were set to 50 mm/sec and 1 mV, respectively. Heart rate (HR) was counted 
from the ECG recording, and respiratory rate (RR) was measured by observing thoracic 
excursions. Bradycardia was defi ned as a heart rate of less than 70 beats minute-1 and 
sinus tachycardia was defi ned as a heart rate of greater than 160 (in large breeds) or 180 
(in small breeds) beats minute-1 (TILLEY, 1992).
The degree of sedation was assessed on a simple descriptive scale of 0-3 (Table 1). 
A person unaware of the treatment was responsible for assessing objective and subjective 
data throughout the study.
Table 1. Description of sedation score categories
Category Description
0 Not sedated. No signs of depression, drowsiness or ataxia
1 Slightly sedated. Mild signs of depression, drowsiness or ataxia. Decreased reaction to stimuli
2 Moderate sedation. Sever ataxia, reluctant to move, may attain sternal recumbency
3 Deep sedation. Depressed, drowsy and sleepy, no resistance to positioning on lateral recumbency
Data analysis. Data distribution for physiologic parameters was tested for 
normality using Shapiro-Wilks testing. One-way ANOVA and Tukey’s test were used 
for comparison of mean values for age, body mass, HR, RR, temperature and onset of 
recumbency between four treatment groups. A paired t-test was used for comparison of 
measured parameters before and after drug injection in each group. A Chi square was 
used to compare the incidence of cardiac dysrhythmias and vomiting. Sedation score was 
compared between the groups by use of the Mann-Whitney test for nonparametric data. 
All data were presented as mean ± SD or Median (25-75th percentile range). Statistical 
analysis was undertaken using the SPSS Version 10 for Windows (SPSS, MicroMaster, 
Richboro, PA, USA) and values of P<0.05 were considered signifi cant.
Results
There were no signifi cant differences between groups for age, body mass and breed 
(Table 2). All drug combinations produced sedation within 20-30 minutes. The median 
sedation score did not differ signifi cantly between the groups; however, the number of 
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dogs assigned score 3 were signifi cantly higher in AXA (P<0.05). Eight dogs that received 
AXA had deep sedation (score 3), whereas only one dog in AX and LA-HX, and 3 dogs in 
HA-LX were assigned score 3. The onset of recumbency (min) tended to be faster in AX 
and AXA treated dogs compared to the other two groups; however, the differences were 
not signifi cant (Table 2). Since some dogs underwent general anaesthesia and surgery 
afterwards, it was not possible to record the duration of sedation.
Table 2. Patient characteristics, type of arrhythmias, sedation score and onset of recumbency in 
dogs receiving Acepromazine-xylazine combination with or without atropine. Data presented as 
mean ± SD or median (25-75th percentile range).
Treatment AX AXA LA-HX HA-LX
Age, yrs 1.8 ± 0.3 2.3 ± 0.4 2.3 ± 0.4 1.3 ± 0.2
Body mass, kg 15.5 ± 7.9 18.3 ± 7.3 20.9 ± 8.1 17.5 ± 10.1
Breed
Large-mixed breed 14 13 18 12
German Shepherd 5 10 7 7
Terrier 5 1 4 7
Spitz 2 3 - 2
Dobermann Pinscher 2 1 - -
Great Dane - - 1 2
Others 2 2 - -
Sex (M:F) 17:13 21:9 18:12 18:12
Type of arrhythmia
First-degree AV block 11 4 6 7
Second-degree AV block - 1 2 1
Sinoatrial block 1 - 1 -
Ventricular tachycardia 1 - 1 2
Sedation score (Median, 25-
75th percentile range)
1 (1-2) 2 (1-3) 2 (1-2) 2 (1-2)
Onset of recumbency, min 14.1 ± 5.4 15.7 ± 5.8 20.0 ± 8.1 20.3 ± 7.6
Defecation/urination 2/1 3/1 4/1 6/3
AX: Acepromazine (0.05 mg/kg) + Xylazine (0.5 mg/kg); AXA: Acepromazine (0.05 mg/kg) + Xylazine (0.5 
mg/kg) + Atropine (0.04 mg/kg); LA-HX: Acepromazine (Low dose: 0.03 mg/kg) + Xylazine (High dose: 0.8 
mg/kg); HA-LX : Acepromazine (High dose: 0.08 mg/kg) + Xylazine (Low dose: 0.3 mg/kg)
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Table 3. Mean ± SD heart rate, respiratory rate and rectal temperature
Treatment AX AXA LA-HX HA-LX
HR (beats minutes-1)
before 109 ± 28 111 ± 27 94 ± 32 116 ± 33
after 76 ± 29* 126 ± 35† 72 ± 23* 89 ± 38*
RR (breaths minutes-1)
before 36 ± 23 45 ± 27 42 ± 39 53 ± 39
after 20 ± 10* 20 ± 12* 30 ± 22* 31 ± 18*
Rectal temperature (°C)
before 38.9 ± 0.7 39.4 ± 0.7 39.4 ± 0.8 39.3 ± 0.5
after 38.5 ± 0.7* 38.6 ± 0.7* 39.2 ± 0.9 38.8 ± 0.7*
*signifi cant differences from before drug injection; † signifi cant differences from other treatments (P<0.05).
The data for HR, RR and rectal temperature before and after the administration of 
drug combinations are summarized in Table 3. The mean values of HR, RR and rectal 
temperature did not differ before drug administration between the treatments. Following 
drug administration, HR decreased in AX, LA-HX and HA-LX (P<0.05). Heart rate was 
signifi cantly higher in dogs receiving AXA compared to the other groups. Bradycardia 
(HR<70 beats minutes-1) was observed in 6, 13 and 15 dogs in HA-LX, LA-HX and AX, 
respectively. Only one dog in the AXA group had bradycardia. 
Before drug administration, positioning in right lateral recumbency and ECG 
recording was possible in only 31 dogs (28.5%), whereas 112 dogs (93.3%) allowed ECG 
recording after drug administration. First-degree AV block was present in one dog in each 
group, except AXA, and two dogs in HA-LX group showed bradycardia or tachycardia 
before drug injection. The incidence of cardiac arrhythmia during maximal sedation was 
similar for all treatments (Table 2). Cardiac arrhythmias were self-correcting with time 
and no treatment was necessary. A signifi cant decrease (28-44%) in RR was observed in 
all treatment groups (P<0.05). There was no apnea or cyanosis in any groups. 
Rectal temperature decreased signifi cantly in AX, AXA and HA-LX treatments during 
maximum sedation (P<0.05). The change in rectal temperature was not signifi cant in LA-
HX. Vomiting was observed in all treatments within 10 minutes after drug injection, in 
5 dogs in AX, 2 dogs in AXA, 1 dog in LA-HX and 4 dogs in HA-LX. Defecation and 
urination were observed in some cases (Table 2). No adverse events were observed during 
the study and all dogs recovered quietly and uneventfully.
Discussion
In this study, identical volumes of drug combinations were given as single IM 
injections in order to avoid distress caused by multiple injections. In the clinical setting, 
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intramuscular injection is the preferred route of drug administration for sedation and 
premedication before general anaesthesia, because minimal restraint is required. Besides, 
cardiovascular responses are attenuated when anticholinergics and α2-agonists are 
administered intramuscularly (VAINIO and PALMU, 1989).
Although the sedative and hemodynamic effects of acepromazine and xylazine 
have been reported previously, the sedative effect of simultaneous administration of 
acepromazine and xylazine in conscious dogs has not been studied to our knowledge. 
When used in combination, the adverse actions of both drugs may be diminished due to 
the lower doses required. Combinations of acepromazine and xylazine and the effects of 
4-aminopyridine and yohimbine, as reversal agents, have been studied in dogs (CRONIN 
et al., 1983). However, the doses of acepromazine and xylazine (0.5 and 2.2 mg kg-1, 
respectively) were much higher than the standard dose and not recommended clinically. 
In healthy dogs, intramuscular doses of acepromazine and xylazine range from 0.05 to 0.2 
mg kg-1 and 0.5 to 1.0 mg.kg-1, respectively (LEMKE, 2007). The acepromazine-xylazine 
combination has been reported to produce better quality sedation than when either drug is 
used alone in horses (MUIR et al., 1979). Administration of acepromazine-xylazine, at twice 
the standard dose, has been used successfully to produce sedation in exercised horses, 
without increasing the untoward effects (HUBBELL et al., 1999). Although the number 
of dogs assigned score 3 were signifi cantly higher in AXA, there were no signifi cant 
differences between the four groups with respect to the degree of fi nal sedation. A more 
sensitive scoring system to assess the level of sedation would improve the chances of 
detecting differences. 
The principal advantage of the acepromazine-xylazine combination is its reversibility 
by administration of selective antagonists (HSU et al., 1985; LEMKE, 2007). Yohimbine 
and 4-aminopyridine, alone or in combination, signifi cantly reduced recovery time 
following acepromazine-xylazine administration in dogs; resedation was not observed 
in any dogs (CRONIN et al., 1983). Reversal with a selective α2-adrenoceptor antagonist 
(i.e., atipamezole) is recommended in situations of inadvertent overdose, when signifi cant 
cardiopulmonary complications occur or residual sedation is undesirable (LEMKE, 2007). 
Complete antagonism of the α2 agonists will reverse both the analgesic and sedative 
effects.
Acepromazine and α2 agonists are frequently used as premedication before general 
anesthesia. Acepromazine administration (0.2 mg kg-1, IM) in dogs anesthetized with 
halothane or isofl urane decreased the MAC by 28% and 48%, respectively (WEBB and 
O’BRIEN, 1988). Preanesthetic administration of acepromazine (0.02 or 0.2 mg.kg-1 i.m.) 
also decreases MAC by 34% and 44% in dogs anesthetized with halothane, respectively 
(HEARD et al., 1986). Xylazine premedication also decreases induction and maintenance 
anesthetic requirements dramatically in dogs (TRANQUILLI et al., 1984). Intravascular 
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administration of xylazine (0.8 mg/kg) decreases the dose of propofol required to induce 
anesthesia in dogs by >50%. The MAC of halothane decreases following xylazine 
administration (1.1 mg kg-1 IV) by 38% (LEMKE, 2007). Although the anesthetic sparing 
effect of acepromazine-xylazine combination is not known, a signifi cant reduction in 
the doses of injectable and inhalational anesthetics is recommended. Clinically, we have 
noticed a 50% reduction in the induction dose of diazepam-ketamine or thiopental, 
following premedication with this drug combination in dogs undergoing general 
anesthesia.
The clinical effi cacy of atropine was tested in one group in order to assess 
the reversibility of the xylazine-induced bradycardia. It seems that the concurrent 
administration of atropine with the acepromazine-xylazine combination enhances the 
degree of sedation. Concurrent drug administration can infl uence the pharmacodynamic 
and pharmacokinetics of drugs. The reason for the higher sedation level in dogs receiving 
AXA can probably be attributed to the marked cardiovascular effects of atropine. 
Atropine, as a small unionized molecule, crosses the blood-brain barrier and may have a 
mild sedative effect when administered at therapeutic doses (LEMKE, 2007). 
The heart rate decreased signifi cantly after AX, LA-HX and HA-LX administration, but 
increased insignifi cantly after administration of AXA. Decreased HR after administration 
of α2-agonist agents has been attributed to augmentation of vagal tone. Development of 
sinus bradycardia and AV block are common after xylazine administration (HASKINS et 
al., 1986; ILBACK and STALHANDSKE, 2003). Anticholinergics have been administered 
with α2-agonists to prevent bradycardia. 
Bradycardia was almost completely prevented by concurrent administration of 
atropine; however, because HR was recorded 15-20 minutes after drug injection, earlier 
bradycardia may have been missed. Atropine inhibits the action of acetylcholine on the 
muscarinic cholinergic receptors and would be a drug of choice when severe bradycardia 
is presented secondary to increased vagal tone (LEMKE, 2007). However, excessive doses 
of atropine may cause sinus tachycardia. It has been reported that prior administration of 
atropine only partially reverses xylazine-induced bradycardia (KLIDE et al., 1975;  HSU et 
al., 1985). The complete reversal of bradycardia in the present study could be attributed to 
the combined effects of atropine and acepromazine. Increases in heart rate may be observed 
in some patients following IV administration of acepromazine in response to peripheral 
vasodilation (LEMKE, 2007). Administration of the acepromazine-xylazine combination 
at very high doses resulted in a slight, insignifi cant increase in HR in dogs premedicated 
with atropine (CRONIN et al., 1983). Due to a possible increase in myocardial oxygen 
demand, combinations of anticholinergics and xylazine are probably best reserved for 
use in young healthy animals and should be avoided in dogs with preexisting myocardial 
diseases (ALIBHAI et al., 1996). However concurrent administration of acepromazine, 
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a potent peripheral vasodilator, may offset the α2-agonist-induced increase in blood 
pressure from vasoconstriction. In this situation, it may make physiological sense to treat 
bradycardia with an anticholinergic. 
Although arterial blood pressure was not measured in the present study, a decrease 
in blood pressure is expected following the acepromazine-xylazine combination, because 
of the combined vasodilatory and negative chronotropic effects of acepromazine and 
xylazine, respectively. In conscious dogs, IV administration of acepromazine (0.1 mg 
kg-1) decreases mean arterial pressure by 20% to 25% for at least 2 hours (STEPIEN et al., 
1995). Intravenous or intramuscular administration of xylazine induces biphasic blood 
pressure response (hypertension followed by hypotension) in dogs (KLIDE et al., 1975; 
HASKINS et al., 1986; ILBACK and STALHANDSKE, 2003); however, the cardiovascular 
effects observed after IM administration of xylazine are less dramatic as compared to IV 
injection (LEMKE, 2007). Cardiac output (CO) and mean arterial blood pressure (ABP) 
decreased after IV administration of a acepromazine (0.05 mg kg-1)-xylazine (0.55 mg kg-
1) combination in horses, but were not signifi cantly different from values obtained after 
acepromazine (0.09 mg kg-1) or xylazine (1.1 mg kg-1) alone (MUIR et al, 1979). In fact, 
these values for the drug combination were midway between the values for either drug 
alone (CO: Acp>Acp-Xyl>Xyl; ABP: Xyl>Acp-Xyl>Acp).
Interestingly, two other studies have shown an increase in arterial blood pressure in 
dogs and exercised horses given the acepromazine-xylazine combination (CRONIN et al., 
1983; HUBBELL et al., 1999). The authors concluded that the lack of hypotensive response 
might be associated with the predominance of the vasoconstrictive effects of xylazine 
or prior atropine administration. The exact mechanism of this unexpected response is 
unknown and deserves further investigation.
The incidence of cardiac arrhythmia was not statistically signifi cant among treatments 
(Table 2). Because ECG was not recorded until maximum sedation was reached (at least 
15 minutes after drug injection), one study limitation is the possible failure to record 
cardiac arrhythmias that may have occurred within minutes of drug administration. 
Although high doses of xylazine appear to sensitize the myocardium to epinephrine-
induced arrhythmias in halothane anesthetized dogs (MUIR et al., 1975; TRANQUILLI et al., 
1986), more recent studies have shown that administration of lower doses of xylazine may 
even attenuate the development of epinephrine-induced arrhythmias in dogs anesthetized 
with halothane or isofl urane (LEMKE et al., 1993a,b). Acepromazine premedication also 
prevents the development of ventricular arrhythmias in halothane-anesthetized dogs 
(MUIR et al., 1975; DYSON and PETTIFER, 1997). The effect of the acepromazine-xylazine 
combination on an arrhythmogenic dose of epinephrine is not known.
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In the present study, the mean respiratory rate decreased markedly by 28-44% in 
dogs treated with the acepromazine-xylazine combination; however, no signs of apnea 
or cyanotic mucous membranes were observed in any of the dogs. In conscious dogs, 
respiratory rate decreases, but arterial pH, partial pressure of carbon dioxide (PCO2), partial 
pressure of oxygen (PO2) and hemoglobin saturation do not change after IV administration 
of acepromazine (STEPIEN et al., 1995). Blood gas values did not change signifi cantly 
following intravenous (1-1.1 mg kg-1) or intramuscular (2.2 mg kg-1) administration of 
xylazine, in spite of signifi cant decreases (by 68%) in respiratory rate (KLIDE et al., 1975, 
HASKINS et al., 1986). The decreased respiratory rate may be attributable to sedation and 
reduced anxiety; however, blood gas values may remain unchanged due to increased 
tidal volume and decreased O2 consumption and CO2 production (HASKINS et al., 1986; 
STEPIEN et al., 1995). Administration of acepromazine-xylazine combination at very high 
doses resulted in 63% reduction in respiratory rate in dogs (CRONIN et al., 1983). No data 
is available regarding the effects of acepromazine-xylazine combination on blood gas 
values.
During maximum sedation, body temperature decreased in the four groups though 
not statistically signifi cantly in the treatment LA-HX. The administration of sedatives 
and tranquilizers generally depress the basal metabolic rate and induce muscle relaxation, 
resulting in lowered body temperature (LEMKE, 2007). Phenothiazines cause peripheral 
vasodilation, which may exaggerate hypothermia (GROSS, 2001). Hypothermia may be 
much more profound in smaller patients due to their larger body surface area to body 
mass ratio. The hypothalamic thermoregulatory center is also affected by phenothiazine 
administration, leading to the loss of thermoregulatory control. The hypothermic effects 
of α2-agonists are mediated by activation of the α2C receptor subtype (LEMKE, 2007). 
However, α2-agonists may reduce cutaneous heat losses by peripheral vasoconstriction 
and central redistribution of blood, resulting in preservation of body temperature. The 
insignifi cant reduction of body temperature in the LA-HX group may be due to the lower 
dose of acepromazine (0.03 mg kg-1) used.
The incidence of vomiting ranged from 3.3 to 16.7 percent and there were no signifi cant 
differences between the four treatment groups. Nausea and vomiting associated with IM 
xylazine administration are caused by activation of the central α2 receptors and prior 
administration of α2-antagonists can prevent emesis (HIKASA et al., 1986). Premedication 
with acepromazine produces an antiemetic effect, which is attributed to the blockade 
of dopamine receptors in the chemoreceptor trigger zone of the medulla. In dogs, prior 
but not simultaneous, administration of acepromazine lowers the incidence of opioid-
induced vomiting (VALVERDE et al., 2004). In the present study, the incidence of vomiting 
was lower (though not statistically signifi cant) in AXA and LA-HX groups. The lower 
incidence of vomiting may be attributable to acepromazine, atropine, or both (LEMKE, 
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2007). It was expected that fewer dogs would vomit in the HA-LX group because of 
the higher dose of acepromazine and lower dose of xylazine; however, the frequency 
of vomiting may be affected by recent feeding in some dogs. Prior administration of 
acepromazine may lower the incidence of xylazine -induced vomiting.
The results of the present study suggested that the acepromazine-xylazine combination 
could be useful for sedation, anxiolysis, muscle relaxation, and premedication in healthy 
dogs. Atropine can be administered simultaneously to prevent the development of 
severe bradycardia and heart blocks. Following the present study, the combination of 
acepromazine-xylazine-atropine has been used for sedation or as premedication before 
general anesthesia in more than 250 dogs in our clinic without any adverse effects. 
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SAŽETAK
Svrha ovog rada bila je klinički procijeniti sedativne učinke različitih doza  acepromazin-ksilazina u 
kombinaciji s atropinom u pasa. Istraživanje je bilo provedeno na 120 nasumce odabranih pasa različitih pasmina 
obaju spolova s dvostruko slijepim probama. Psi su bili klinički obrađivani na jednoj veterinarskoj klinici zbog 
potrebe za različitim dijagnostičkim i kirurškim pregledima. Za potrebe istraživanja bili su podijeljeni u četiri 
skupine (30 pasa po skupini), a po skupinama su intramuskularno dobivali sljedeće kombinacije lijekova: skupina 
AX dobivala je acepromazin (0,05 mg kg-1) i ksilazin (0,5 mg kg-1), skupina AXA dobivala je acepromazin 
(0,05 mg kg-1), ksilazin (0,5 mg kg-1) i atropin (0,04 mg kg-1), skupina LA-HX dobivala je acepromazin (malu 
dozu od 0,03 mg kg-1) i ksilazin (veliku dozu od 0,8 mg kg-1), a skupina HA-LX acepromazin (veliku dozu od 
0,08 mg kg-1) i ksilazin (malu dozu od 0,3 mg kg-1). Vrijednosti bila, frekvencije disanja, elektrokardiograma i 
rektalne temperature bile su izmjerene prije davanja sedativa te za vrijeme maksimalne sedacije. Sedacija je bila 
bodovana opisno.  Vrijednosti bila značajno su se smanjile nakon sedacije u pasa skupina AX, LA-HX i HA-
LX. Značajno smanjena frekvencija disanja bila je zabilježena u svim skupinama. Srednji broj bodova sedacije 
nije se značajno razlikovao među skupinama, ali je kvaliteta sedacije bila  bolja kada je atropin bio dodan 
kombinaciji acepromazin-ksilazin te su tri boda bila dodijeljena većem broju pasa u skupini AXA. Nuspojave 
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nisu bile zabilježene. Kombinacija acepromazin-ksilazin, osobito s atropinom, može se rabiti za učinkovitu 
sedaciju i premedikaciju prije opće anestezije u zdravih pasa. 
Ključne riječi: acepromazin, atropin, pas, sedacija, ksilazin
